According to Spherix Global Insights, nephrologists overwhelmingly chose the DAPA-CKD trial as the most compelling among the eight presented during...
Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains...
The SGLT2 inhibitor class, specifically Janssen’s Invokana (promoted by Relypsa in nephrology), is gaining momentum with nephrologists as potential DKD...
According to Spherix Global Insights, nephrologists anxiously await pipeline products such as Retrophin’s sparsentan, Aurinia’s voclosporin, Reata’s bardoxolone methyl, and...
The firm, which was recently recognized by Philadelphia Business Journal as one of the area’s Soaring 76 fastest growing companies...
According to a recently published report by Spherix Global Insights, after rapid trial of Lokelma in hyperkalemia, treatment patterns are...
An independent audit conducted by Spherix Global Insights analyzed the charts of more than 1,000 patients with moderate to severe...
According to Spherix Global Insights, the potential approval of the hypoxia-inducible factors prolyl-hydroxylase inhibitors could alter referral and treatment patterns...
According to Spherix Global Insights, just one-tenth of specialty physician offices are operating at normal capacity, and doctors report facing...
According to Spherix Global Insights’ latest quarterly survey of 101 US nephrologists, despite anticipated increases in use, over one-third of...
According to feedback from the sixth wave of COVID-19 impact tracking, Spherix Global Insights finds that patient volumes remain severely...
The impact to practices has been severely disruptive, taking a devastating personal and financial toll on specialty physicians according to...
